Onima Chowdhury
MA BM BCh MRCP FRCPath DPhil
Clinician Scientist
- Consultant Haematologist
Biography
Over the past decade there has been an explosion in single cell sequencing technologies. My research focus is to apply these novel technologies to improve the diagnosis and care of patients with myeloid malignancies.
I trained in medicine at the University of Cambridge and then the University of Oxford. I then undertook my specialist haematology training at UCL and Oxford, completing a DPhil at Oxford in 2014 with Professor Sten Eirik Jacobsen, focussing on the characterisation of stem cells in myeloid malignancies. I was then awarded an NIHR Academic Clinical Lectureship, where I investigated the mutational landscape in patients with a specific myeloid malignancy (myelofibrosis) and the relationship with response to treatment.
I am currently a consultant haematologist in the Haematology department at Oxford University Hospitals where I look after patients with myeloid malignancies and am also a clinical lead in the diagnostics laboratory. I was awarded an MRC Clinical Academic Research Partnership Award in 2020 focussing on clinical application of single cell sequencing for early diagnosis and response prediction in myeloid malignancies in collaboration with Professor Mead.
Key publications
- 
                            
    
        
            
                Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide.Journal article Chowdhury O. et al, (2021), Leukemia, 35, 1197 - 1202 
- 
                            
    
        
            
                Niche-mediated depletion of the normal hematopoietic stem cell reservoir by Flt3-ITD-induced myeloproliferation.Journal article Mead AJ. et al, (2017), J Exp Med, 214, 2005 - 2021 
- 
                            
    
        
            
                A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.Journal article Svensson T. et al, (2014), Eur J Haematol, 93, 439 - 445 
- 
                            
    
        
            
                Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivoJournal article Woll PS. et al, (2014), Cancer Cell, 25, 794 - 808 
- 
                            
    
        
            
                Impact of isolated germline JAK2V617I mutation on human hematopoiesis.Journal article Mead AJ. et al, (2013), Blood, 121, 4156 - 4165